JP2012516140A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516140A5
JP2012516140A5 JP2011546814A JP2011546814A JP2012516140A5 JP 2012516140 A5 JP2012516140 A5 JP 2012516140A5 JP 2011546814 A JP2011546814 A JP 2011546814A JP 2011546814 A JP2011546814 A JP 2011546814A JP 2012516140 A5 JP2012516140 A5 JP 2012516140A5
Authority
JP
Japan
Prior art keywords
polypeptide
isolated
cell
oligopeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011546814A
Other languages
English (en)
Japanese (ja)
Other versions
JP5792630B2 (ja
JP2012516140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/050839 external-priority patent/WO2010086294A2/en
Publication of JP2012516140A publication Critical patent/JP2012516140A/ja
Publication of JP2012516140A5 publication Critical patent/JP2012516140A5/ja
Application granted granted Critical
Publication of JP5792630B2 publication Critical patent/JP5792630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011546814A 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Active JP5792630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14789209P 2009-01-28 2009-01-28
EP09151495 2009-01-28
EP09151495.0 2009-01-28
US61/147,892 2009-01-28
PCT/EP2010/050839 WO2010086294A2 (en) 2009-01-28 2010-01-26 Pan-dr binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2012516140A JP2012516140A (ja) 2012-07-19
JP2012516140A5 true JP2012516140A5 (OSRAM) 2013-03-14
JP5792630B2 JP5792630B2 (ja) 2015-10-14

Family

ID=42025833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546814A Active JP5792630B2 (ja) 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用

Country Status (4)

Country Link
US (2) US9249187B2 (OSRAM)
EP (1) EP2391635B1 (OSRAM)
JP (1) JP5792630B2 (OSRAM)
WO (1) WO2010086294A2 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP3028048B1 (en) 2013-07-31 2018-09-26 BioVentures, LLC Compositions for treating and preventing cancer targeting tumor associated carbohydrate antigens
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
CN109748952B (zh) 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
SG11202012313PA (en) * 2018-06-13 2021-01-28 Scripps Research Inst Nanoparticle vaccines with novel structural components
US20220383996A1 (en) 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
CA3243638A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg CONJUGATED CONSISTING OF OR COMPRISING AT LEAST ONE SS-GLUCANE OR ONE MANNANE
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
PT534618E (pt) 1991-08-26 2006-08-31 Scripps Research Inst Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b
CA2115839C (en) 1991-08-26 2010-06-01 Maria A. Vitiello Hla-restricted hepatitis b virus ctl epitopes
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
WO2003040165A2 (en) 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US20040096445A1 (en) 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
WO2004031211A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
DE69434954T2 (de) 1993-02-26 2007-12-20 The Scripps Research Institute, La Jolla Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
AU6916694A (en) 1993-05-19 1994-12-12 Cytel Corporation Novel treatments for allergic diseases
CA2168583C (en) 1993-08-02 2007-10-02 Francis V. Chisari Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
WO1995004817A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
WO1995004542A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
AU6103896A (en) 1995-06-07 1996-12-30 Cytel Corporation Manufacture and purification of peptides
BR9710404A (pt) * 1996-01-24 1999-08-17 Epimmune Inc Indu-Æo de resposta imune contra determinantes desejados
EP0914142B9 (en) * 1996-03-11 2012-01-04 Epimmune Inc. Peptides with increased binding affinity for at least three hla-a3-like molecules
AU2658897A (en) 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
WO2004089973A2 (en) 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
AU6140998A (en) 1997-01-31 1998-08-25 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
ATE364048T1 (de) 1997-10-10 2007-06-15 Us Gov Health & Human Serv Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
JP2002507397A (ja) 1998-03-13 2002-03-12 エピミューン，インコーポレイティド Ｈｌａ結合ペプチド及びその使用
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
ATE429247T1 (de) 1998-06-17 2009-05-15 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
PL202399B1 (pl) 1998-10-05 2009-06-30 Pharmexa As Zastosowanie adiuwanta i pierwszego analogu polipeptydowego antygenu związanego z komórką lub co najmniej jednego fragmentu kwasu nukleinowego kodującego epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką lub niepatogennego mikroorganizmu lub wirusa, który niesie fragment kwasu nukleinowego, który koduje i wyraża co najmniej jeden epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką, sposób selekcji immunogennego analogu antygenu polipeptydowego związanego z komórką, sposób wytwarzania komórki wytwarzającej analog an
WO2000044775A2 (en) 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
WO2002019986A1 (en) 2000-09-08 2002-03-14 Epimmune Inc. Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
AU6226100A (en) 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
JP4873810B2 (ja) 1999-10-05 2012-02-08 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導
JP4776131B2 (ja) 1999-11-18 2011-09-21 エピミューン インコーポレイテッド ヘテロクリティックアナログおよび関連方法
WO2001042270A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1235841A4 (en) 1999-12-10 2006-04-12 Epimmune Inc TRIGGERING MAGE2 / 3 CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
JP2003530083A (ja) 1999-12-10 2003-10-14 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ＨＥＲ２／ｎｅｕに対する細胞性免疫応答の誘導
WO2001041788A1 (en) 1999-12-10 2001-06-14 Epimmune, Inc. INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
WO2001041741A1 (en) 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
JP2003521245A (ja) 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
DK1242108T3 (da) 1999-12-28 2007-11-12 Pharmexa Inc Optimerede minigener og peptider kodet derved
MXPA02008219A (es) 2000-02-23 2005-06-30 Epimmune Inc Peptidos que enlazan hla y sus usos.
EP1619207A3 (en) 2000-09-01 2006-02-08 Epimmune Inc. HLA-A2.1 binding peptides derived from HCV and their uses
CA2421448A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
JP2004522415A (ja) 2000-09-01 2004-07-29 エピミューン インコーポレーティッド Ｈｌａ結合ペプチドおよびその使用方法
US20060018915A1 (en) 2002-04-05 2006-01-26 Glenn Ishioka Heteroclitic analogs and related methods
WO2004031210A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
ES2498371T3 (es) 2002-12-06 2014-09-24 Epimmune Inc. Antígenos de Plasmodium falciparum y procedimientos de uso
AU2003296330A1 (en) 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
EP1609107A4 (en) 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
DK1620456T3 (da) 2003-04-18 2014-04-22 Biotech Synergy Inc Hla-a2 tumor-associerede antigen-peptider og præparater
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2005089164A2 (en) 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
AU2005250170A1 (en) 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
EP1781326A4 (en) 2004-06-04 2009-01-14 Pharmexa Inc INDUCTION OF AN IMMUNE RESPONSE AGAINST STREPTOCOKE PENUMONIA POLYSACCHARIDES
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2007137586A2 (en) 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides
WO2008039267A2 (en) 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US9910646B2 (en) 2015-12-26 2018-03-06 Intel Corporation Technologies for native code invocation using binary analysis

Similar Documents

Publication Publication Date Title
JP2012516140A5 (OSRAM)
JP6826027B2 (ja) インフルエンザ抗原送達用のベクターおよび構築体
Babin et al. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP
JP2013517783A5 (OSRAM)
JP2014500724A5 (OSRAM)
JP2014503172A5 (OSRAM)
JP2010529860A5 (OSRAM)
JP2015521467A5 (OSRAM)
JP2012501959A5 (OSRAM)
JP2009540801A5 (OSRAM)
JP2011516070A5 (OSRAM)
JP2015501656A5 (OSRAM)
JP2019506175A5 (OSRAM)
JP2015212284A5 (OSRAM)
JP2006187292A5 (OSRAM)
JP2015509707A5 (OSRAM)
JP2017521064A5 (OSRAM)
JP2012515557A5 (OSRAM)
BR112015013387B1 (pt) Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
JP2010532656A5 (OSRAM)
HRP20130022T1 (hr) Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora
JP2014504297A5 (OSRAM)
JP2020502075A5 (OSRAM)
Cho et al. Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus